Merck/Bayer set to challenge Novartis in heart failure after phase 3 trial successMerck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, Share XMerck/Bayer set to challenge Novartis in heart failure after phase 3 trial successhttps://pharmaphorum.com/news/merck-bayers-heart-failure-drug-on-target-at-phase-3/
NICE backs NHS funding for two cannabis-based drugs for first timeNICE has recommended two of GW Pharma’s cannabis-based medicines, the first time that medicines derived from the plant Share XNICE backs NHS funding for two cannabis-based drugs for first timehttps://pharmaphorum.com/news/nice-includes-bayer-gws-cannabis-based-sativex-in-ms-guideline-for-first-time/
Which big pharma firms are best at digital?New research by The Worldcom Public Relations Group has ranked pharmaceutical companies according to their usage of digital Share XWhich big pharma firms are best at digital?https://pharmaphorum.com/views-analysis-digital/which-big-pharma-firms-are-best-at-digital/
FDA approves Bayer/Janssen’s Xarelto in new blood clot prevention useBayer and Janssen’s novel oral anticoagulant (NOAC) Xarelto has a new string to its bow after the FDA Share XFDA approves Bayer/Janssen’s Xarelto in new blood clot prevention usehttps://pharmaphorum.com/news/fda-approves-bayer-janssens-xarelto-in-new-blood-clot-prevention-use/
Bayer chooses UK for its AI-focused R&D hubBayer has continued its policy of setting up R&D hubs to get closer to innovative companies with a Share XBayer chooses UK for its AI-focused R&D hubhttps://pharmaphorum.com/news/bayer-chooses-uk-for-its-artificial-intelligence-focused-rd-hub/
Novartis’ new eye drug undercuts Bayer’s rival with fewer injectionsThe FDA has approved Novartis’s new eye drug brolucizumab for wet age-related macular degeneration, which will match Bayer’s Share XNovartis’ new eye drug undercuts Bayer’s rival with fewer injectionshttps://pharmaphorum.com/news/novartis-new-eye-drug-undercuts-bayers-rival-with-less-frequent-dosing/
How to make digital adoption a smooth journeyFour big pharma experts explain the challenges companies face in adopting digital tech and what trends are likely Share XHow to make digital adoption a smooth journeyhttps://pharmaphorum.com/views-analysis-sales-marketing/digital-adoption-smooth-journey/
MHRA says Avastin can be used for AMD despite Bayer, Novartis objectionsThe UK drugs regulator has endorsed the use of Roche’s Avastin as a treatment for age-related macular degeneration, Share XMHRA says Avastin can be used for AMD despite Bayer, Novartis objectionshttps://pharmaphorum.com/news/mhra-says-avastin-can-be-used-for-amd-despite-bayer-novartis-objections/
Bayer’s Vitrakvi is first tumour-agnostic drug approved in EUBayer’s TRK inhibitor Vitrakvi has been approved by the EMA, becoming the first therapy for cancer based on Share XBayer’s Vitrakvi is first tumour-agnostic drug approved in EUhttps://pharmaphorum.com/news/bayers-vitrakvi-is-first-tumour-agnostic-drug-approved-in-eu/
